Kestra Advisory Services’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Kestra Advisory Services's SABS Position: Q3 2026 in Review
Kestra Advisory Services held its SAB Biotherapeutics (SABS) position steady in Q3 2026 at 49,811 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #3304.
Kestra Advisory Services first reported a position in SABS in Q2 2022 and has held it in 16 quarters since. The position peaked at $236K in Q1 2026. 100 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Kestra Advisory Services held 49,811 shares of SAB Biotherapeutics worth $158K as of Q3 2026.
- Kestra Advisory Services left its SAB Biotherapeutics share count unchanged in Q3 2026.
- SAB Biotherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #3304 holding.
- Kestra Advisory Services first reported a position in SAB Biotherapeutics in Q2 2022 and has held it in 16 quarters since.
- Kestra Advisory Services's SAB Biotherapeutics position peaked at $236K in Q1 2026.
- 100 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.